“Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies” (2021) SKIN The Journal of Cutaneous Medicine, 5(6), p. s66. doi:10.25251/skin.5.supp.66.